BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16143789)

  • 1. Treatment planning consideration for prostate implants with the new linear RadioCoil 103Pd brachytherapy source.
    Meigooni AS; Awan SB; Rachabatthula V; Koona RA
    J Appl Clin Med Phys; 2005; 6(3):23-36. PubMed ID: 16143789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric characteristics of the new RadioCoil 103Pd wire line source for use in permanent brachytherapy implants.
    Meigooni AS; Zhang H; Clark JR; Rachabatthula V; Koona RA
    Med Phys; 2004 Nov; 31(11):3095-105. PubMed ID: 15587663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
    Chibani O; Williamson JF; Todor D
    Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brachytherapy dosimetry parameters calculated for a new 103Pd source.
    Rivard MJ; Melhus CS; Kirk BL
    Med Phys; 2004 Sep; 31(9):2466-70. PubMed ID: 15487726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy assessment of the superposition principle for evaluating dose distributions of elongated and curved 103Pd and 192Ir brachytherapy sources.
    Bannon EA; Yang Y; Rivard MJ
    Med Phys; 2011 Jun; 38(6):2957-63. PubMed ID: 21815369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of TG-43 recommended 2D-anisotropy function for elongated brachytherapy sources.
    Awan SB; Meigooni AS; Mokhberiosgouei R; Hussain M
    Med Phys; 2006 Nov; 33(11):4271-9. PubMed ID: 17153405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the dose distribution for prostate implants using various 125I and 103Pd sources.
    Meigooni AS; Luerman CM; Sowards KT
    Med Phys; 2009 Apr; 36(4):1452-8. PubMed ID: 19472652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models.
    Thomson RM; Rogers DW
    Med Phys; 2010 Jan; 37(1):368-76. PubMed ID: 20175499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brachytherapy dosimetry of 125I and 103Pd sources using an updated cross section library for the MCNP Monte Carlo transport code.
    Bohm TD; DeLuca PM; DeWerd LA
    Med Phys; 2003 Apr; 30(4):701-11. PubMed ID: 12722822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations.
    Li XA; Wang JZ; Stewart RD; DiBiase SJ
    Phys Med Biol; 2003 Sep; 48(17):2753-65. PubMed ID: 14516099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cylindrical coordinate based TG-43U1 parameters for dose calculation around elongated brachytherapy sources.
    Awan SB; Dini SA; Hussain M; Soleimani-Meigooni D; Meigooni AS
    J Appl Clin Med Phys; 2008 Apr; 9(2):123-142. PubMed ID: 18714281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monte Carlo dosimetric characterization of the IsoAid ADVANTAGE 103Pd brachytherapy source.
    Sowards KT
    J Appl Clin Med Phys; 2007 Mar; 8(2):18-25. PubMed ID: 17592461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric study of a new polymer encapsulated palladium-103 seed.
    Bernard S; Vynckier S
    Phys Med Biol; 2005 Apr; 50(7):1493-504. PubMed ID: 15798339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monte Carlo calculation of dosimetry parameters for the IR08-103Pd brachytherapy source.
    Saidi P; Sadeghi M; Shirazi A; Tenreiro C
    Med Phys; 2010 Jun; 37(6):2509-15. PubMed ID: 20632562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monte carlo investigation of the dosimetric properties of the new 103Pd BrachySeedPd-103 Model Pd-1 source.
    Chan GH; Prestwich WV
    Med Phys; 2002 Sep; 29(9):1984-90. PubMed ID: 12349919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theoretical and experimental determination of dosimetric characteristics for ADVANTAGE Pd-103 brachytherapy source.
    Meigooni AS; Dini SA; Awan SB; Dou K; Koona RA
    Appl Radiat Isot; 2006 Aug; 64(8):881-7. PubMed ID: 16713277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edema-induced increase in tumour cell survival for 125I and 103Pd prostate permanent seed implants--a bio-mathematical model.
    Yue N; Chen Z; Nath R
    Phys Med Biol; 2002 Apr; 47(7):1185-204. PubMed ID: 11996063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calculated microdosimetric characteristics of 125I and 103Pd brachytherapy seeds at different depths in water.
    Wuu CS; Chen J
    Radiat Prot Dosimetry; 2006; 122(1-4):506-8. PubMed ID: 17189276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monte Carlo calculations and experimental measurements of dosimetric parameters of the IRA-103Pd brachytherapy source.
    Sadeghi M; Raisali G; Hosseini SH; Shavar A
    Med Phys; 2008 Apr; 35(4):1288-94. PubMed ID: 18491522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription dose in permanent (131)Cs seed prostate implants.
    Yue N; Heron DE; Komanduri K; Huq MS
    Med Phys; 2005 Aug; 32(8):2496-502. PubMed ID: 16193779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.